middle.news
Mesoblast’s Ryoncil Launch Sparks 191% Revenue Surge Amid FDA Milestone
3:39am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Mesoblast’s Ryoncil Launch Sparks 191% Revenue Surge Amid FDA Milestone
3:39am on Saturday 30th of August, 2025 AEST
Key Points
FDA approval and commercial launch of Ryoncil for pediatric SR-aGvHD
191% increase in cell therapy revenue to US$17.2 million
Strong cash position of US$162 million supports growth
Plans for label expansions in adults and inflammatory bowel disease
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE